Opendata, web and dolomites


GlioDx - Blood platelet-based monitoring and treatment optimisation for glioblastoma patients

Total Cost €


EC-Contrib. €






Project "GlioDx" data sheet

The following table provides information about the project.


Organization address
address: DE BOELELAAN 1117
postcode: 1081 HV

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2018-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 150˙000.00
2    STICHTING VU NL (AMSTERDAM) participant 0.00


 Project objective

Glioblastoma (GBM) is a devastating primary brain cancer which affects about 230.000 people annually. The choice for treatment depends on the subtype of GBM. An accurate detection of tumour subtype is therefore essential for a personalised targeted treatment. Diagnosis, classification and treatment monitoring occurs currently by radiology and repeated invasive biopsies. There is a need for non-invasive, actionable biomarkers for early-stage diagnosis and disease monitoring. During our ERC research, we discovered that mRNA sequenced from tumour-educated platelets enables for pan-cancer, multiclass cancer and companion diagnostics. We were able to distinguish between primary and metastasised tumours in the brain and also establish the molecular subtype of the tumour. These findings provide strong support for using tumour-educated platelets as a biomarker for early stratification, diagnosis and prognosis for personalised GBM treatment.

As a proof-of-concept of our innovative diagnostic tests, we will validate the proprietary algorithms underlying these tests specifically in GBM patients. To achieve this, we focus on the differentiation of glioblastoma subtype based on the platelet mRNA profile. In addition we will validate treatment monitoring and response prediction to an EGFR targeted drug in GBM patients.

GlioDx will also assess the feasibility to commercialise the technology. The team has developed several business and IP models which need to be assessed thoroughly through in-depth market research and business planning activities. The results need to be consolidated into a strong business plan that will be presented to investors and strategic investors.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

sociOlfa (2020)

Learning from social scents: from territory to identity

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

CN Identity (2019)

Comprehensive anatomical, genetic and functional identification of cerebellar nuclei neurons and their roles in sensorimotor tasks

Read More